AIDS Patent Pool Garners Support From Industry, But Pharma Companies Want Flexibility In Pricing Between Countries
This article was originally published in PharmAsia News
Executive Summary
The drug purchasing group UNITAID may succeed in getting pharmaceutical companies to pool patents on their AIDS medicines. So far, it has won buy-in of the idea from three: Gilead Sciences, Merck and Johnson & Johnson subsidiary Tibotec
You may also be interested in...
Medicines Patent Pool Takes Novel Approach With Roche In Valcyte Deal
Roche and the Medicines Patent Pool have signed a five-year deal that will allow developing countries to achieve faster access to the Swiss company’s CMV drug, Valcyte for 90% less.
ViiV Healthcare's Pipeline Sharing With Generic Makers "Meaningless" In Absence Of Technology - Cipla, IPA
MUMBAI - Cipla - India's biggest generic drug maker and among the largest manufacturers of generic anti-retroviral drugs in the world - expressed measured optimism to ViiV Healthcare's decision on offering access to the portfolio of its present and future pipeline of anti-retroviral medicines to 69 least developed and low-income countries without any royalty charges. Even so, a Cipla spokesman said he doubted if the steps announced on improving access to the medicines can be implemented
ViiV Healthcare's Pipeline Sharing With Generic Makers "Meaningless" In Absence Of Technology - Cipla, IPA
MUMBAI - Cipla - India's biggest generic drug maker and among the largest manufacturers of generic anti-retroviral drugs in the world - expressed measured optimism to ViiV Healthcare's decision on offering access to the portfolio of its present and future pipeline of anti-retroviral medicines to 69 least developed and low-income countries without any royalty charges. Even so, a Cipla spokesman said he doubted if the steps announced on improving access to the medicines can be implemented